Twice-Yearly Shot Shows Promise in Ending AIDS, But Access Remains a Hurdle
A Shot at Ending AIDS: new HIV Prevention Drug Raises Hope, But Access Concerns Loom
A groundbreaking twice-yearly injection has shown nearly 100% effectiveness in preventing HIV infection, offering a potential game-changer in the fight against AIDS. However, concerns are mounting over limited access to the drug in Latin America, a region grappling wiht rising HIV rates.
The injectable drug, lenacapavir, marketed as Sunlenca, has already been approved for HIV treatment in the U.S., Canada, Europe, and other countries. Recent clinical trials revealed its remarkable success in preventing HIV infection, particularly among women.While other prevention methods like condoms, daily pills, and bi-monthly shots exist, experts believe the twice-yearly injection could be a lifeline for marginalized communities often hesitant to seek traditional care.
“It would be a miracle for these groups because it means they just have to show up twice a year at a clinic and then they’re protected,” said Winnie Byanyima, executive director of UNAIDS.
Drugmaker Gilead has pledged to make generic versions of the drug available in 120 low- and middle-income countries, primarily in Africa, Southeast Asia, and the Caribbean. However, this agreement excludes most of Latin America, where HIV rates are rising despite being lower than in other regions.
This exclusion has sparked alarm among health experts and advocates who fear a missed opportunity to curb the epidemic.
“In Latin American countries, there is still a lot of stigma, patients are ashamed to ask for the pills,” said Dr. Alma Minerva Pérez, a researcher in Guadalajara, Mexico, who participated in the clinical trials.
Luis ruvalcaba, a 32-year-old man from Guadalajara who participated in the study, shared Dr. Pérez’s concerns.He admitted to being afraid to request daily prevention pills due to fear of discrimination as a gay man.The exclusion of Latin America from the generic agreement raises questions about equitable access to this potentially life-saving drug.while mexico’s public health system began offering free daily HIV prevention pills in 2021, the availability and affordability of the new injection remain uncertain.
“If the possibility of using generics has opened, I have faith that Mexico can join,” said Dr. Pérez, expressing hope for wider access in the future.
The World AIDS Day report from UNAIDS highlighted a significant decline in AIDS-related deaths, reaching its lowest point as 2004. This progress underscores the potential to end the epidemic, but experts emphasize that achieving this goal hinges on ensuring equitable access to innovative prevention tools like the new injectable drug.
Groundbreaking HIV Prevention Shot Remains out of Reach for Millions in Latin America
New injectable drug hailed as a game-changer in the fight against HIV is unavailable in many hard-hit countries, sparking outrage from activists.
A revolutionary new injectable drug, Sunlenca, has been hailed as a potential game-changer in the fight against HIV, offering long-lasting protection with just two shots a year. However, millions in Latin America, a region grappling with rising HIV infection rates, are being denied access to this potentially life-saving medication.
Gilead Sciences,the maker of Sunlenca,has granted licenses for generic production in 120 countries,primarily in Africa. This decision has left out most of latin America, where HIV rates are alarmingly on the rise, particularly among vulnerable populations like gay men and transgender individuals.
“it’s unconscionable to deny access to this drug in countries like Brazil, Peru, and Argentina,” said Asia Russell, executive director of the advocacy group Health Gap. “We’re talking about a drug that could prevent countless infections and save lives.”
Activists are calling on Gilead to expand access to Sunlenca in latin America, citing the urgent need for effective HIV prevention tools in the region.
“We’re seeing a public health emergency unfold in latin America,” said Dr. Chris Beyrer,director of the Global Health Institute at duke University. “While sunlenca is a breakthrough for Africa and Asia, we can’t ignore the crisis happening right here in our own hemisphere.”
Hannya Danielle Torres,a 30-year-old trans woman and artist who participated in the Sunlenca trial in Mexico,expressed her hope that the government would find a way to make the drug accessible.
“Mexico has both immense wealth and extreme poverty,” Torres said. “We need to ensure that everyone, regardless of their socioeconomic status, has access to this life-saving medication.”
The high cost of Sunlenca, which can exceed $40,000 per year in some countries, is a major barrier to access. Experts estimate that generic production could bring the cost down to as low as $40 per treatment, making it affordable for even the most resource-constrained countries.
Some countries, like Colombia, have taken matters into their own hands, issuing compulsory licenses to bypass patent restrictions and produce generic versions of essential HIV medications. This strategy, previously used for AIDS drugs in the late 1990s and 2000s, could be a viable solution for ensuring access to Sunlenca in latin America.
Dr. Salim abdool Karim, an AIDS expert at South Africa’s University of KwaZulu-Natal, emphasized the urgency of the situation.
“Sunlenca has the potential to be a truly transformative drug in the fight against HIV,” he said. “But its effectiveness is meaningless if it’s not available to those who need it most.”
The fight for access to Sunlenca in Latin America highlights the ongoing struggle to ensure equitable access to life-saving medications globally. as the world celebrates advancements in HIV prevention, it’s crucial to remember that the battle is far from over.
A Shot of Hope, a Dose of Inequality: Lenacapavir’s Promise and Latin america’s Access Crisis
NewsDirectory3.com Exclusive Interview
The global fight against AIDS received a potentially monumental boost with the emergence of lenacapavir, a revolutionary twice-yearly injection boasting near-100% effectiveness in preventing HIV infection.Hailed as a game-changer, particularly for vulnerable populations, the drug, marketed as Sunlenca, has garnered praise from health experts and advocates alike. However, a shadow of concern looms over its rollout. While Gilead, the drugmaker, has pledged to make generic versions accessible to numerous low- and middle-income countries, a glaring omission – Latin America – threatens to undermine the drug’s potential impact.
We sat down with Dr. Alma Minerva Pérez, a leading researcher in Guadalajara, Mexico, who participated in the lenacapavir clinical trials, to delve deeper into this complex issue.
NewsDirectory3.com: Dr. Pérez, the initial findings on lenacapavir are undeniably promising. How meaningful a breakthrough is this drug, especially in the context of existing HIV prevention methods?
Dr. Pérez: The potential of lenacapavir is truly astounding.it offers a long-acting solution that coudl revolutionize HIV prevention, particularly for marginalized communities who face numerous barriers accessing conventional methods like daily pills or condoms.
NewsDirectory3.com: We understand your involvement in the clinical trials. Could you shed light on the experiences of participants, particularly in relation to stigma and access to care?
Dr.Pérez: My experience,and that of many participants,highlighted the deep-seated stigma surrounding HIV,especially in Latin America.
Many individuals are hesitant to seek testing or access PrEP due to fear of discrimination based on their sexuality or perceived risk factors.
NewsDirectory3.com: Gilead’s agreement to provide generic versions of lenacapavir is commendable. Though,the exclusion of most Latin american countries from this agreement raises serious concerns. What are the potential consequences of this
omission?
Dr. Pérez: It’s deeply troubling. By excluding Latin America, we risk exacerbating existing inequities and denying a potentially life-saving tool to a region struggling with rising HIV rates.
Imagine Luis,a participant in our trial,who shared his struggle with fear and discrimination. He was reluctant to take daily pills due to the stigma attached to being a gay man seeking HIV prevention. Lenacapavir could have been a lifeline for him, offering discreet and effective protection.
Without access to this drug, countless individuals like Luis will remain vulnerable and at risk.
NewsDirectory3.com: What message do you have for gilead and other stakeholders regarding the need for equitable access to lenacapavir in Latin America?
Dr. Pérez: We urge Gilead to reconsider their exclusion of Latin America from the generic agreement. Providing equitable access to lenacapavir is not only a matter of public health but a moral imperative.
Global health challenges demand collaborative solutions. We need a concerted effort from governments, NGOs, and pharmaceutical companies to ensure that this groundbreaking drug reaches those who need it most, irrespective of their geographical location.
The fight against AIDS is far from over. Lenacapavir offers a beacon of hope, but its impact will be severely limited if access remains a privilege rather than a right.